<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834938</url>
  </required_header>
  <id_info>
    <org_study_id>LIMED0005</org_study_id>
    <nct_id>NCT00834938</nct_id>
  </id_info>
  <brief_title>Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery</brief_title>
  <official_title>Long Term Effects of Bariatric Surgery on Diabetes: Comparison Between Patients With or Without Diabetes Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery can lead to improvement or even resolution of type 2 diabetes in about 80%
      of patients submitted to Roux-en-Y gastric bypass (RYGP). Otherwise, many patients
      experienced no resolution of their diabetes despite massive surgical-induced weight loss.
      There appears to be a variable response to surgery depending on surgical and patient factors.
      To explore potential factors affecting diabetes outcomes after RYGP, this study is proposed
      to make a description of effects of surgical procedures on incretin, insulin production and
      sensitivity and a comparison between patients with or without remission of Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes reversion is observed after bariatric surgeries even before significant weight loss
      could explain it, mainly in predominantly malabsorptive procedures (98,9% for biliopancreatic
      diversion or duodenal switch), followed by those combining malabsorption and gastric
      restriction (83,7% for Roux-en-Y gastric bypass). Changes in the hormonal communication
      between the digestive system and the pancreas would explain the antidiabetogenic role of the
      surgery, so this effect could be obtained in nonobese, diabetic individuals.

      To explore potential factors affecting diabetes outcomes after RYGP, this study is proposed
      to make a description of effects of surgical procedures on incretin, insulin production and
      sensitivity and a comparison between patients with or without remission of Type 2 Diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the endogenous response of incretins, orexins and anorexins to a mixed meal test in obese patients with DM2, in patients with DM2 undergoing RYGB with remission of DM2 and in patients without remission.</measure>
    <time_frame>2 years after RYGB</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with DM2 undergoing RYGB with remission of DM2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with DM2 undergoing RYGB without remission of DM2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with DM2 and obesity undergoing RYGB with remission of DM2 and without remission.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to understand the procedures of the study.

          -  To agree voluntarily to participate of the study, signing an informed consent.

          -  Weight variance less than 5% in the last 3 months.

          -  Operative group with at least 2 year follow-up.

        Exclusion Criteria:

          -  History of hepatic disease like cirrhosis or chronic active hepatitis.

          -  Kidney dysfunction (creatinine &gt; 1,4 mg/dl in women and &gt; 1,5 mg/dl in men).

          -  Hepatic dysfunction: ALT and/or AST 3x above upper normal limit).

          -  Recent history of neoplasia (&lt; 5 years).

          -  Use of oral or injectable for more than consecutive 14 days in the last three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Carlos Pareja, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Geloneze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/Univeristy of Campinas (UNICAMP)</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM, Pareja JC. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg. 2003 Feb;13(1):17-22.</citation>
    <PMID>12630608</PMID>
  </reference>
  <reference>
    <citation>Geloneze B, Tambascia MA, Pareja JC, Repetto EM, Magna LA. The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res. 2001 Dec;9(12):763-9.</citation>
    <PMID>11743060</PMID>
  </reference>
  <reference>
    <citation>Pories WJ, MacDonald KG Jr, Flickinger EG, Dohm GL, Sinha MK, Barakat HA, May HJ, Khazanie P, Swanson MS, Morgan E, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992 Jun;215(6):633-42; discussion 643.</citation>
    <PMID>1632685</PMID>
  </reference>
  <reference>
    <citation>Pories WJ. Diabetes: the evolution of a new paradigm. Ann Surg. 2004 Jan;239(1):12-3.</citation>
    <PMID>14685094</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fernanda Maria Possidonio Filgueira Hirsch</name_title>
    <organization>UNICAMP</organization>
  </responsible_party>
  <keyword>diabetes mellitus, type 2</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Gastric Inhibitory Polypeptide</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>ghrelin</keyword>
  <keyword>adiponectin</keyword>
  <keyword>Cytokines</keyword>
  <keyword>gastric bypass</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

